The firm will develop Sareum's FLT3+Aurora kinases portfolio, including SAR-20293, a preclinical drug candidate for acute myeloid leukaemia and other blood-borne cancers.
Sareum Holdings new licensing deal 'could generate significant near-term milestone revenue'
Quick facts: Sareum Holdings PLC
Price: 0.71 GBX
Market Cap: £21.81 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Sareum Holdings PLC named herein, including the promotion by the Company of Sareum Holdings PLC in any Content on the Site, the Company...FOR OUR FULL DISCLAIMER CLICK HERE